Who is sponsoring NCT04469699?

NCT04469699 is sponsored by University Hospital Muenster.

What condition does NCT04469699 study?

NCT04469699 studies Glioblastoma Multiforme, Adult.

Is NCT04469699 still recruiting?

NCT04469699 is currently terminated. Last updated 11 March 2025.

Last reviewed 2025-03-11 · How we verify

NCT04469699: NOA11

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma

Terminated Phase 2 Last updated 11 March 2025

What this trial tests

Phase 2 trial testing Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid in Glioblastoma Multiforme, Adult in 30 participants. Terminated before completion.

Timeline

12 April 2021

Primary endpoint
30 January 2025

30 January 2025

Quick facts

Lead sponsor	University Hospital Muenster
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	12 April 2021
Primary completion	30 January 2025
Estimated completion	30 January 2025
Sites	4 locations across Germany

Drugs / interventions tested

Stereotactic biopsy followed by stereotactical photodynamic therapy with 5-aminolevulinic acid — full drug profile →
Stereotactic biopsy

Conditions studied

Glioblastoma Multiforme, Adult — all drugs for Glioblastoma Multiforme, Adult →

Sponsor

University Hospital Muenster

Who can join

Adults 18 to 75, any sex, with Glioblastoma Multiforme, Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this multicenter, randomized, non-blinded trial the efficacy and safety of stereotactical photodynamic therapy with 5-aminolevulinic acid will be investigated in 106 patients with recurrent glioblastoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Photodynamic Therapy for the Treatment and Diagnosis of <i>Cancer</i>-A Review of the Current Clinical Status.
Gunaydin G, Gedik ME, Ayan S. · · 2021 · cited 225× · PMID 34409014 · DOI 10.3389/fchem.2021.686303
Advances in local therapy for glioblastoma - taking the fight to the tumour.
van Solinge TS, Nieland L, Chiocca EA, Broekman MLD. · · 2022 · cited 219× · PMID 35277681 · DOI 10.1038/s41582-022-00621-0
Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, López-Blanch R, et al · · 2024 · cited 147× · PMID 38473776 · DOI 10.3390/ijms25052529
Safe surgery for glioblastoma: Recent advances and modern challenges.
Gerritsen JKW, Broekman MLD, De Vleeschouwer S, Schucht P, et al · · 2022 · cited 59× · PMID 36127890 · DOI 10.1093/nop/npac019
Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.
Penetra M, Arnaut LG, Gomes-da-Silva LC. · · 2023 · cited 36× · PMID 37346450 · DOI 10.1080/2162402x.2023.2226535
ROS regulation in gliomas: implications for treatment strategies.
Yang YC, Zhu Y, Sun SJ, Zhao CJ, et al · · 2023 · cited 34× · PMID 38130720 · DOI 10.3389/fimmu.2023.1259797
Systematic Review of Photodynamic Therapy in Gliomas.
Hsia T, Small JL, Yekula A, Batool SM, et al · · 2023 · cited 32× · PMID 37568734 · DOI 10.3390/cancers15153918
Photodynamic Therapy for Glioblastoma: Illuminating the Path toward Clinical Applicability.
Bhanja D, Wilding H, Baroz A, Trifoi M, et al · · 2023 · cited 30× · PMID 37444537 · DOI 10.3390/cancers15133427

Verify or expand the search:

Other recruiting trials for Glioblastoma Multiforme, Adult

Currently open trials in the same condition.

NCT05653622 — Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operate · Phase 2 · recruiting
NCT06496971 — A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubbl · Phase 3 · recruiting
NCT05954858 — Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma · NA · recruiting
NCT06954636 — Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study · recruiting
NCT05720078 — UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) · NA · recruiting

Other University Hospital Muenster trials

Trials by the same sponsor.

NCT07414498 — MICRO-SURG: Subgingival Microbiome in Peri-Implantitis, Regenerative, and Resective Periodontal Surgery · NA · not yet recruiting
NCT06999174 — Multiparametric MRI for Characterization of Hepatocellular Carcinoma · recruiting
NCT06980740 — Video-Tumorboard PLUS · recruiting
NCT06648733 — Improving Pharmacological Transition of Palliative Care Patients From Inpatient to Outpatient Care · NA · recruiting
NCT06464302 — Investigation of the Effect of Age and Injury Severity on Short-term Intra-hospital Outcomes After Surgical Stabilized R · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04469699 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital Muenster
Last refreshed: 11 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04469699.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing